JP2015506922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506922A5 JP2015506922A5 JP2014547635A JP2014547635A JP2015506922A5 JP 2015506922 A5 JP2015506922 A5 JP 2015506922A5 JP 2014547635 A JP2014547635 A JP 2014547635A JP 2014547635 A JP2014547635 A JP 2014547635A JP 2015506922 A5 JP2015506922 A5 JP 2015506922A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- acid
- branched
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- AKEXREJPEFSHCT-UHFFFAOYSA-N 10-hydroxydecanoyl (9Z,12Z)-octadeca-9,12-dienoate Chemical compound C(CCCCCCCC=C/CC=C/CCCCC)(=O)OC(CCCCCCCCCO)=O AKEXREJPEFSHCT-UHFFFAOYSA-N 0.000 claims 2
- UEGWWOVMHDARPA-UHFFFAOYSA-N 10-hydroxydecanoyl (Z)-octadec-9-enoate Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CCCCCCCCCO)=O UEGWWOVMHDARPA-UHFFFAOYSA-N 0.000 claims 2
- KJTGDTBDBDFAFO-UHFFFAOYSA-N 16-hydroxyhexadecanoyl (9Z,12Z)-octadeca-9,12-dienoate Chemical compound C(CCCCCCCC=C/CC=C/CCCCC)(=O)OC(CCCCCCCCCCCCCCCO)=O KJTGDTBDBDFAFO-UHFFFAOYSA-N 0.000 claims 2
- KOITVLVSMOBKGI-KTKRTIGZSA-N 16-hydroxyhexadecanoyl (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCO KOITVLVSMOBKGI-KTKRTIGZSA-N 0.000 claims 2
- UUFGOXJUPRNHBR-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCC)OC(CCCCCCCCCCCCCCCO)=O Chemical compound C(CCCCCCCCCCCCCCCCC)OC(CCCCCCCCCCCCCCCO)=O UUFGOXJUPRNHBR-UHFFFAOYSA-N 0.000 claims 2
- CRWBYIMWBAJWTE-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCC)OC(CCCCCCCCCO)=O Chemical compound C(CCCCCCCCCCCCCCCCC)OC(CCCCCCCCCO)=O CRWBYIMWBAJWTE-UHFFFAOYSA-N 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- GDQHLDVYOKCEEY-UHFFFAOYSA-N [(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl] 10-hydroxydecanoate Chemical compound C(CCCC=C/CC=C/CC=C/CC=C/CCCCC)OC(=O)CCCCCCCCCO GDQHLDVYOKCEEY-UHFFFAOYSA-N 0.000 claims 2
- AYUXZRXXCQWNOK-UHFFFAOYSA-N [(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl] 16-hydroxyhexadecanoate Chemical compound C(CCCC=C/CC=C/CC=C/CC=C/CCCCC)OC(CCCCCCCCCCCCCCCO)=O AYUXZRXXCQWNOK-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FBWMYSQUTZRHAT-HZJYTTRNSA-N (9z,12z)-octadeca-9,12-dienoyl chloride Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(Cl)=O FBWMYSQUTZRHAT-HZJYTTRNSA-N 0.000 claims 1
- MLQBTMWHIOYKKC-KTKRTIGZSA-N (z)-octadec-9-enoyl chloride Chemical compound CCCCCCCC\C=C/CCCCCCCC(Cl)=O MLQBTMWHIOYKKC-KTKRTIGZSA-N 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 239000004902 Softening Agent Substances 0.000 claims 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 carbomer 980 Polymers 0.000 claims 1
- 229940085237 carbomer-980 Drugs 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 229950008138 carmellose Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905421 | 2011-12-23 | ||
| AU2011905421A AU2011905421A0 (en) | 2011-12-23 | Ophthalmic Formulation | |
| PCT/AU2012/001595 WO2013091020A2 (en) | 2011-12-23 | 2012-12-21 | Ophthalmic formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506922A JP2015506922A (ja) | 2015-03-05 |
| JP2015506922A5 true JP2015506922A5 (enExample) | 2016-02-18 |
| JP6087374B2 JP6087374B2 (ja) | 2017-03-01 |
Family
ID=48669621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547635A Active JP6087374B2 (ja) | 2011-12-23 | 2012-12-21 | 眼科用製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10385003B2 (enExample) |
| EP (3) | EP2794550B1 (enExample) |
| JP (1) | JP6087374B2 (enExample) |
| KR (3) | KR102080951B1 (enExample) |
| CN (1) | CN104271548B (enExample) |
| AU (1) | AU2012318266B2 (enExample) |
| BR (1) | BR112014015430B1 (enExample) |
| CA (1) | CA2859997C (enExample) |
| CO (1) | CO7101242A2 (enExample) |
| DK (1) | DK2794550T3 (enExample) |
| ES (1) | ES2716806T3 (enExample) |
| HU (1) | HUE042760T2 (enExample) |
| MX (1) | MX364693B (enExample) |
| PL (1) | PL2794550T3 (enExample) |
| PT (1) | PT2794550T (enExample) |
| RU (1) | RU2625301C2 (enExample) |
| SI (1) | SI2794550T1 (enExample) |
| TR (1) | TR201902752T4 (enExample) |
| WO (1) | WO2013091020A2 (enExample) |
| ZA (1) | ZA201404642B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102080951B1 (ko) | 2011-12-23 | 2020-05-28 | 웨스턴 시드니 유니버시티 | 안과용 제형물 |
| JP2020525416A (ja) * | 2017-06-29 | 2020-08-27 | アドヴァイテ エルエルシー． | 眼表面障害の治療及び診断 |
| NO345574B1 (en) | 2018-06-19 | 2021-04-26 | Epax Norway As | Composition for treatment of dry eye disease and meibomianitis |
| US20240226052A1 (en) * | 2021-04-30 | 2024-07-11 | Helsingin Yliopisto | A specific combination of lipids and methods and uses related thereto |
| CN115607534A (zh) * | 2021-07-16 | 2023-01-17 | 云南拜奥泰克生物技术有限责任公司 | 一种mlct替代睑酯油及其制备方法 |
| FI20225982A1 (en) * | 2022-11-02 | 2024-05-03 | Univ Helsinki | New formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2855047B1 (fr) * | 2003-05-19 | 2007-11-30 | Oreal | Composition comprenant une base sphingoide, un activateur de la voie des 4-et/ou des 6-hydroxylases et un acide gras, utilisation pour renforcer la fonction barriere de la peau |
| US8455016B2 (en) * | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
| US8569367B2 (en) * | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
| AU2008219600A1 (en) * | 2007-02-28 | 2008-09-04 | Aciex Therapeutics, Inc. | Methods and compositions for normalizing meibomian gland secretions |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| KR102080951B1 (ko) | 2011-12-23 | 2020-05-28 | 웨스턴 시드니 유니버시티 | 안과용 제형물 |
-
2012
- 2012-12-21 KR KR1020147020528A patent/KR102080951B1/ko active Active
- 2012-12-21 WO PCT/AU2012/001595 patent/WO2013091020A2/en not_active Ceased
- 2012-12-21 ES ES12860686T patent/ES2716806T3/es active Active
- 2012-12-21 HU HUE12860686A patent/HUE042760T2/hu unknown
- 2012-12-21 CN CN201280069966.XA patent/CN104271548B/zh active Active
- 2012-12-21 JP JP2014547635A patent/JP6087374B2/ja active Active
- 2012-12-21 RU RU2014129437A patent/RU2625301C2/ru active
- 2012-12-21 AU AU2012318266A patent/AU2012318266B2/en active Active
- 2012-12-21 US US14/367,836 patent/US10385003B2/en active Active
- 2012-12-21 EP EP12860686.0A patent/EP2794550B1/en active Active
- 2012-12-21 PT PT12860686T patent/PT2794550T/pt unknown
- 2012-12-21 EP EP24203699.4A patent/EP4494707A3/en active Pending
- 2012-12-21 PL PL12860686T patent/PL2794550T3/pl unknown
- 2012-12-21 DK DK12860686.0T patent/DK2794550T3/en active
- 2012-12-21 CA CA2859997A patent/CA2859997C/en active Active
- 2012-12-21 EP EP18187476.9A patent/EP3459929A1/en not_active Withdrawn
- 2012-12-21 TR TR2019/02752T patent/TR201902752T4/tr unknown
- 2012-12-21 BR BR112014015430-9A patent/BR112014015430B1/pt active IP Right Grant
- 2012-12-21 MX MX2014007629A patent/MX364693B/es active IP Right Grant
- 2012-12-21 SI SI201231543T patent/SI2794550T1/sl unknown
- 2012-12-21 KR KR1020207004568A patent/KR102291754B1/ko active Active
- 2012-12-21 KR KR1020217025498A patent/KR20210104916A/ko not_active Ceased
-
2014
- 2014-06-24 ZA ZA2014/04642A patent/ZA201404642B/en unknown
- 2014-07-22 CO CO14158909A patent/CO7101242A2/es unknown
-
2019
- 2019-07-18 US US16/515,387 patent/US20200190015A1/en not_active Abandoned
-
2021
- 2021-05-12 US US17/318,581 patent/US20210403410A1/en not_active Abandoned
-
2024
- 2024-03-18 US US18/608,522 patent/US20240368069A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7745892B2 (ja) | Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
| JP2015506922A5 (enExample) | ||
| JP6589086B2 (ja) | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 | |
| JP2015531344A5 (enExample) | ||
| KR20180080189A (ko) | 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물 | |
| HRP20210726T1 (hr) | Ciklički dinukleotidi kao antagonisti sting (stimulatora interferonskih gena) | |
| KR20120115380A (ko) | 마이봄선 기능 장애의 치료 방법 | |
| JP2016515561A5 (enExample) | ||
| SI3023415T1 (en) | Histone demethylase inhibitors | |
| FI3258919T4 (fi) | Nasaalinen jauheformulaatio hypoglykemian hoitoon | |
| JP2019516739A5 (enExample) | ||
| BR122019026750B1 (pt) | Compostos antagonistas de integrina fluorados | |
| JP2016511753A5 (enExample) | ||
| AR117219A1 (es) | Formulaciones en cápsulas, método de preparación | |
| JP2015508068A5 (enExample) | ||
| RU2014129437A (ru) | Офтальмологическая композиция | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP5542059B2 (ja) | Ｒｘｒ作動性物質を有効成分とする抗アレルギー剤 | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| JP2014530204A5 (enExample) | ||
| JP2015511618A5 (enExample) | ||
| JP2018504391A5 (enExample) | ||
| JP2013529686A5 (enExample) | ||
| TW201811307A (zh) | 2-(2-乙氧基-2-氧代乙基)(甲基)胺基-2-氧代乙基5-(十四烷氧基)呋喃-2-羧酸酯之皮膚調配物 | |
| JP2013510845A5 (enExample) |